News Release

A secreted signature of aging cells

Peer-Reviewed Publication


A Secreted Signature of Aging Cells

image: SASP Atlas: A Comprehensive Resource for Senescence-Associated Secretory Phenotypes. <a href="" target="_blank">SASP Atlas</a> is a curated and freely available database of the secretomes of senescent cells, including both the soluble and exosome SASP, that can be used to identify SASP components or biomarker candidates for senescence burden, aging and related diseases. view more 

Credit: Birgit Schilling

Senescent cells undergo an irreversible and permanent arrest of cell division and are hallmarks of both the aging process and multiple chronic diseases. Senescent cells - and more importantly the factors they secrete, known collectively as the senescence-associated secretory phenotype (SASP) - are widely accepted as drivers of aging and multiple age-related diseases.

A new study publishing on January 16 in the open-access journal PLOS Biology from Drs. Nathan Basisty, Judith Campisi, Birgit Schilling (Buck Institute for Research on Aging) and colleagues extensively profiles the SASP in human cells. They show that a core secreted protein "signature" of senescent cells is enriched with aging biomarkers found in human plasma.

The study utilizes a comprehensive and unbiased technique called mass spectrometry combined with bioinformatics to develop secreted protein signatures of senescent cells. The researchers' results show that the SASP is about ten-fold more complex than is currently appreciated, allowing them to propose new signatures of senescent cells - both 'core' signatures shared across all senescent cells and signatures that identify specific subsets of senescent cells.

Mouse studies have demonstrated that the targeted removal of senescent cells has beneficial effects on cardiac, vascular, metabolic, neurological, renal, pulmonary and musculoskeletal functions. Therefore, the selective elimination of senescent cells or inhibition of the SASP that they secrete are promising therapeutic approaches to treat age-related diseases in humans. Development of drugs that eliminate senescent cells, known as senolytics, or drugs that inhibit the SASP, known as senomorphics, requires molecular markers to assess the abundance of senescent cells. However, there are currently no simple reliable secreted biomarkers to measure the senescent cell burden in humans.

"We hope that these biomarker signatures will help us measure the burden of senescent cells in human biofluids, such as plasma, to aid the translation of senescence-targeted therapies into the clinic," says Dr Basisty. "We believe that the proteins secreted by senescent cells will also be important biomarkers for aging, neurodegenerative diseases, and other diseases marked by the presence of senescent cells."

Along with this study, the researchers launched the SASP Atlas, a curated database of proteins secreted by senescent cells. This resource can be used by others in the research community to identify proteins originating from senescent cells in their own research.


Peer-reviewed; Experimental Study; Cells

In your coverage please use this URL to provide access to the freely available article in PLOS Biology:

Citation: Basisty N, Kale A, Jeon OH, Kuehnemann C, Payne T, Rao C, et al. (2020) A proteomic atlas of senescence-associated secretomes for aging biomarker development. PLoS Biol 18(1): e3000599.

Funding: This work was supported by grants from the National Institute on Aging (BS is supported by U01 AG060906-02, Principal Investigator: Schilling; JC is supported by P01AG017242 and R01AG051729, Principal Investigator: Campisi) and a National Institutes of Health Shared Instrumentation Grant (BS is supported by 1S10 OD016281, Buck Institute). NB and OHJ were supported by postdoctoral fellowships from the Glenn Foundation for Medical Research. AK was supported by the SENS Foundation. VS was supported by the University of Washington, Seattle Proteomics Resource (UWPR95794). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: I have read the journal's policy and the authors of this manuscript have the following competing interests: JC is a founder and shareholder of Unity Biotechnology, which develops senolytic drugs. All other authors have declared no competing interests.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.